Journal of Hand Surgery
Volume 33, Issue 7 , Pages 1211-1214 , September 2008

Current Management of Onychomycosis

  • Kara S. Nunley, MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Kara S. Nunley, MD, Division of Dermatology, Washington University School of Medicine, Campus Box 8123, 660 South Euclid Ave., St. Louis, MO 63110-1010
    • ,
  • Lynn Cornelius, MD

Received 18 April 2008 ,Accepted 26 May 2008.

References 

  1. Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43:244–248
  2. Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol. 1998;38:702–704
  3. Paus R, Peker S, Sundberg JP. Biology of hair and nails. In:  Bolognia JL editors. Dermatology. 2nd ed.. Amsterdam: Elsevier; 2008;p. 965–986
  4. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126(Suppl 39):2–7
  5. Gupta AK, Ryder JE. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin. 2003;21:469–479
  6. Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther. 2007;20:31–46
  7. Scher RK, Breneman D, Rich P, Savin RC, Feingold DS, Konnikov N, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38:S87–S86
  8. Thiim M, Friedman LS. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis. 2003;7:381–399
  9. Gupta AK, Tu LQ. Therapies for onychomycosis: a review. Dermatol Clin. 2006;24:375–379
  10. Katz HI, Gupta AK. Oral antifungal drug interactions. Dermatol Clin. 1997;15:535–544
  11. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150:537–544
  12. Mishra M, Panda P, Tripathy S, Sengupta S, Mishra K. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol. 2005;71:262–266
  13. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(Suppl 4):S70–S80
  14. Jaiswal A, Sharma RP, Garg AP. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol. 2007;73:393–396
  15. Baran R, Sigurgeirsson B, de Berker D, Kaufmann R, Lecha M, Faergemann J, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol. 2007;157:149–157
  16. Loo DS. Onychomycosis in the elderly: drug treatment options. Drugs Aging. 2007;24:293–302
  17. Gupta AK. Systemic antifungal agents. In:  Wolverton SE editors. Comprehensive dermatologic drug therapy. 2nd ed.. St. Louis, MO: Elsevier; 2008;p. 75–99
  18. Tavakkol A, Fellman S, Kianifard F. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis- and Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial. Am J Geriatr Pharmacother. 2006;4:1–13

 No benefits in any form have been received or will be received related directly or indirectly to the subject of this article.

PII: S0363-5023(08)00436-X

doi: 10.1016/j.jhsa.2008.05.028

Journal of Hand Surgery
Volume 33, Issue 7 , Pages 1211-1214 , September 2008

Article Tools